Emerging treatments in Castleman disease – a critical appraisal of siltuximab
Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD) is a rare, heterogeneous lymphoproliferative disorder for which no standard of care currently exists. Evidence that the pathophysiology of...
Main Authors: | Koff JL, Lonial S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-01-01
|
Series: | Biologics : Targets & Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/emerging-treatments-in-castleman-disease-ndash-a-critical-appraisal-of-peer-reviewed-article-BTT |
Similar Items
-
The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
by: Gi-June Min, et al.
Published: (2021-03-01) -
Impact of siltuximab on patient-related outcomes in multicentric Castleman’s disease
by: Sitenga J, et al.
Published: (2018-01-01) -
Update and new approaches in the treatment of Castleman disease
by: Chan KL, et al.
Published: (2016-08-01) -
TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
by: Corinne Williams, et al.
Published: (2021-09-01) -
A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease
by: Alexandra Butzmann, et al.
Published: (2021-03-01)